The need for neuropsychiatry clinical trials to evolve is crucial. Traditional measures lack sensitivity, elevating the need for novel, objective measures of drug target engagement to offset or combat placebo effects. Additionally, the impact of neuropsychiatric conditions on cognition has gained broad interest across the pharmaceutical industry. This webinar highlights the latest advances in neurotech, which enable the collection of real-world objective data, and features key findings from a Phase Ib study presented at the 38th European College of Neuropsychiatry (ECNP) annual meeting.
One example of this evolving landscape is a clinical-stage neuroscience program advancing DLX-001 (zalsupindole), a novel neuroplastogen in development for the treatment of major depressive disorder. The broader therapeutic approach centers on neuroplasticity-promoting compounds intended to address treatment-resistant neuropsychiatric and neurological conditions.
The featured speakers in this webinar will showcase data demonstrating the power of EEG for measuring drug target engagement and cognition in a clinical trial for major depressive disorder, an area with continued unmet clinical need.
Register today to learn how sensitive, objective, real-world data collection can accelerate the evolution of neuropsychiatric clinical trials and the clinical development of effective CNS therapies to improve the lives of millions of people living with neuropsychiatric conditions.
Speakers
Dr. Aaron Koenig, MD, CMO, Delix Therapeutics
Dr. Koenig has been the Chief Medical Officer at Delix Therapeutics for over two years. A diplomate of the American Board of Psychiatry and Neurology, he holds active board certifications in both Adult and Geriatric Psychiatry. Dr. Koenig earned his MD from the University of Pennsylvania, followed by a residency in Adult Psychiatry at the Western Psychiatric Institute & Clinic of UPMC, where he was also Chief Resident for Research. He completed a fellowship in Geriatric Psychiatry at the Hospital of the University of Pennsylvania and a post-doctoral research fellowship in Psychiatric Genetics at Harvard.
Before joining Delix, he served as Vice President of Early Medical Science at Sage Therapeutics, where he led the design and execution of their clinical-stage neuropsychiatry programs. His career also includes a faculty appointment at Harvard Medical School and clinical work at Massachusetts General Hospital’s Memory Disorders Unit.
Message Presenter
Dr. Brian Murphy, PhD, Co-Founder and CSO, Cumulus Neuroscience
Dr. Brian Murphy is the Co-Founder and Chief Scientific Officer at Cumulus Neuroscience. He is a Computational Neuroscientist and an expert in brain-reading technology, utilizing machine learning methods to decode cognitive states from recordings of brain activity (EEG, fMRI and MEG) and other data sources. His academic career included positions as an Assistant Professor in Data Science at Queen’s University Belfast, as Senior Researcher at Carnegie Mellon University’s Department of Machine learning and a post-doc at the Centre for Mind/Brain Sciences, University of Trento, Italy. He has a PhD in Cognitive Science from Trinity College Dublin and, prior to academia, worked in and co-founded web startups in Germany and China. Brian is a member of the Alzheimer’s Association EEG PIA committee and organised the MLINI series of workshops on machine learning with neuroimaging data at NeurIPS, the world’s leading machine learning conference.
Message PresenterWho Should Attend?
This webinar will appeal to professionals focused on diseases in the CNS space in the following fields:
- Biopharma Translational R&D
- Biopharma Clinical R&D
- Biopharma Clinical Operations
- Medical Affairs
- CROs
What You Will Learn
Attendees will:
- Hear from CNS thought-leaders on the transformative power of objective measures of brain function in neuropsychiatry clinical trials
- Learn how digital biomarkers have the potential to transform neuropsychiatry clinical trials much the same way that next-generation sequencing has transformed oncology, enabling personalized treatment
- Gain insight into the power of EEG data synchronized with behavioural assessment data for measuring drug target engagement and cognition in a clinical trial for major depressive disorder
Xtalks Partner
Cumulus Neuroscience
With a mission to generate the data and insights required to accelerate diagnosis and management of central nervous system (CNS) disorders for millions of patients and caregivers around the world, Cumulus Neuroscience is advancing NeuLogiq®, an AI-based, multi-domain digital biomarker platform to enable better, faster decision making in neurology and neuropsychiatry clinical trials and patient care. Designed for and with 10 of the world’s leading pharma companies, the platform enables decentralized trials, and is already making a difference in the development of therapies for Alzheimer’s Disease, depression and schizophrenia.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account